MX2021014039A - Composiciones y métodos para mejorar resultados de tratamiento para pacientes que tienen neoplasias malignas hematológicas usando un producto de células madre expandidas. - Google Patents
Composiciones y métodos para mejorar resultados de tratamiento para pacientes que tienen neoplasias malignas hematológicas usando un producto de células madre expandidas.Info
- Publication number
- MX2021014039A MX2021014039A MX2021014039A MX2021014039A MX2021014039A MX 2021014039 A MX2021014039 A MX 2021014039A MX 2021014039 A MX2021014039 A MX 2021014039A MX 2021014039 A MX2021014039 A MX 2021014039A MX 2021014039 A MX2021014039 A MX 2021014039A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- stem cell
- patients
- cell product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos y composiciones para tratar una neoplasia maligna hematológica con un producto de células madre hematopoyéticas expandidas en combinación con un régimen de quimioterapia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962849588P | 2019-05-17 | 2019-05-17 | |
US201962852147P | 2019-05-23 | 2019-05-23 | |
PCT/US2020/033182 WO2020236612A1 (en) | 2019-05-17 | 2020-05-15 | Compositions and methods for improving treatment outcomes for patients having hematological malignancies using an expanded stem cell product |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014039A true MX2021014039A (es) | 2022-02-11 |
Family
ID=73458649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014039A MX2021014039A (es) | 2019-05-17 | 2020-05-15 | Composiciones y métodos para mejorar resultados de tratamiento para pacientes que tienen neoplasias malignas hematológicas usando un producto de células madre expandidas. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220218759A1 (es) |
EP (1) | EP3969018A4 (es) |
JP (1) | JP2022533191A (es) |
KR (1) | KR20220020277A (es) |
CN (1) | CN114173795A (es) |
AU (1) | AU2020279938A1 (es) |
CA (1) | CA3138292A1 (es) |
IL (1) | IL288161A (es) |
MX (1) | MX2021014039A (es) |
WO (1) | WO2020236612A1 (es) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009521930A (ja) * | 2005-12-29 | 2009-06-11 | アントフロゲネシス コーポレーション | 胎盤幹細胞及び第2供給源由来幹細胞の共存培養 |
EP2555782A1 (en) * | 2010-04-09 | 2013-02-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function without hla matching |
CA3090548A1 (en) * | 2010-04-09 | 2011-10-13 | Fred Hutchinson Cancer Research Center | Compositions and methods for providing hematopoietic function |
JP6047489B2 (ja) * | 2010-08-12 | 2016-12-21 | フェイト セラピューティクス,インコーポレイテッド | 改善された造血幹細胞および前駆細胞療法 |
US9834755B2 (en) * | 2011-12-08 | 2017-12-05 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
KR20160079854A (ko) * | 2013-10-31 | 2016-07-06 | 프레드 헛친슨 켄서 리서치 센터 | 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도 |
WO2016176652A2 (en) * | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
WO2018075408A1 (en) * | 2016-10-17 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin |
WO2019023189A1 (en) * | 2017-07-24 | 2019-01-31 | The Brigham And Women's Hospital, Inc. | TARGETING ESSENTIAL GENES IN ACUTE MYELOID LEUKEMIA (AML) |
CN111542341A (zh) * | 2017-10-25 | 2020-08-14 | 锕医药股份有限公司 | 基于抗-cd45的淋巴细胞消减方法及其与基于act的癌症疗法的联合应用 |
-
2020
- 2020-05-15 KR KR1020217041440A patent/KR20220020277A/ko active Search and Examination
- 2020-05-15 US US17/611,829 patent/US20220218759A1/en active Pending
- 2020-05-15 MX MX2021014039A patent/MX2021014039A/es unknown
- 2020-05-15 JP JP2021568721A patent/JP2022533191A/ja active Pending
- 2020-05-15 AU AU2020279938A patent/AU2020279938A1/en active Pending
- 2020-05-15 CN CN202080051637.7A patent/CN114173795A/zh active Pending
- 2020-05-15 EP EP20809569.5A patent/EP3969018A4/en active Pending
- 2020-05-15 CA CA3138292A patent/CA3138292A1/en active Pending
- 2020-05-15 WO PCT/US2020/033182 patent/WO2020236612A1/en active Application Filing
-
2021
- 2021-11-16 IL IL288161A patent/IL288161A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220218759A1 (en) | 2022-07-14 |
AU2020279938A1 (en) | 2021-12-16 |
WO2020236612A1 (en) | 2020-11-26 |
CN114173795A (zh) | 2022-03-11 |
EP3969018A1 (en) | 2022-03-23 |
KR20220020277A (ko) | 2022-02-18 |
JP2022533191A (ja) | 2022-07-21 |
EP3969018A4 (en) | 2023-07-12 |
CA3138292A1 (en) | 2020-11-26 |
IL288161A (en) | 2022-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
PH12017550063A1 (en) | Combination therapies for treating cancers | |
MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
PH12019502661A1 (en) | Articles of manufacture and methods for treatment using adoptive cell therapy | |
MX2022007472A (es) | Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario. | |
MX2018004599A (es) | Terapia de combinacion para el tratamiento de neoplasias malignas. | |
MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX2018006831A (es) | Metodos de tratamiento de neoplasias malignas. | |
MY199019A (en) | Pd-1 antibodies | |
MX2015014431A (es) | Monoterapia con glucopiranosil lipido a para usarse en el tratamieto del cancer. | |
NZ708249A (en) | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor | |
MX2020008022A (es) | Composiciones para uso en operaciones de petroleo y gas. | |
MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
MX2018004586A (es) | Terapia de combinacion para tratar tumores malignos. | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
MX2019002728A (es) | Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2018000267A (es) | Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. | |
MD4685C1 (ro) | Metodă de tratament al stărilor asociate cu activarea complementului dependentă de MASP-2 | |
MX2020010269A (es) | Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. | |
TR201811308T4 (tr) | Kanser kok hücrelerini azaltan anti-emp2 tedavisi. | |
WO2018208954A3 (en) | Peptidomimetic macrocycles and uses thereof | |
MX2022010466A (es) | Tratamiento conjunto contra tipos de cancer hematologico. | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
MX2020013103A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. |